Related Experiment Videos
Interrelationship between serum and fecal sterols.
Japanese Journal of Medicine
|January 1, 1983
Summary
Intestinal flora convert dietary cholesterol into coprostanol. Lower conversion rates correlate with higher serum cholesterol, suggesting a key role for gut bacteria in cholesterol regulation.
Area of Science:
- Gastroenterology
- Microbiology
- Metabolic Research
Background:
- Dietary cholesterol intake and fecal sterol excretion vary significantly among individuals.
- Intestinal microflora play a role in sterol metabolism.
Purpose of the Study:
- To investigate the relationship between intestinal flora activity, fecal sterol composition, and serum cholesterol levels.
- To determine the role of cholesterol conversion to coprostanol by gut bacteria in cholesterol regulation.
Main Methods:
- Dietary intervention with controlled cholesterol intake (359 mg/day) in healthy volunteers and hospitalized patients.
- Analysis of fecal cholesterol and coprostanol levels, including the coprostanol/cholesterol ratio.
- In vitro anaerobic incubation of feces with egg yolk to assess intestinal flora activity.
- Measurement of de novo cholesterol synthesis.
- Determination of fecal sterol amounts in additional hospitalized patients.
Main Results:
- Significant inter-individual variation in fecal cholesterol and coprostanol excretion was observed (coprostanol/cholesterol ratio: 0.01–4.27).
- Lower coprostanol excretion was associated with higher beta-sitosterol and crude fiber excretion, indicating reduced intestinal flora activity.
- An inverse relationship was found between serum cholesterol levels and the fecal coprostanol/cholesterol ratio in hospitalized patients.
- De novo cholesterol synthesis ranged from 0.1–0.6 g/day.
Conclusions:
- Intestinal flora's conversion of cholesterol to coprostanol varies significantly among individuals.
- This conversion process may be a crucial factor in regulating serum cholesterol levels.
- Gut microbial activity in sterol metabolism represents a potential therapeutic target for managing hypercholesterolemia.